The Faber Difference
Values & Community
Our Clients
Areas of Expertise
Launching a drug development company with novel technology from academia
Our corporate group has worked with hundreds of entrepreneurs at this stage to help them optimally and efficiently select and form the appropriate legal entity - while our licensing professionals have drafted and negotiated countless agreements securing intellectual rights to foundational technologies
Getting ready for a global Phase 2 or 3 clinical trial
Our experienced contracts specialists work alongside attorneys steeped in the business side of life sciences
Establishing a pharmaceutical supply chain
Our team of professionals understands the industry-specific drivers of complex supply chains
The Faber Difference
Values & Community
Our Clients
Areas of Expertise
Launching a drug development company with novel technology from academia
Our corporate group has worked with hundreds of entrepreneurs at this stage to help them optimally and efficiently select and form the appropriate legal entity - while our licensing professionals have drafted and negotiated countless agreements securing intellectual rights to foundational technologies
Getting ready for a global Phase 2 or 3 clinical trial
Our experienced contracts specialists work alongside attorneys steeped in the business side of life sciences
Establishing a pharmaceutical supply chain
Our team of professionals understands the industry-specific drivers of complex supply chains
News
On April 30th, Faber Principal, Jodi Stanfield, and Counsel, Gina Wu, participated in a discussion on Informed Consent Forms (ICFs) in clinical studies, focusing on the similarities and differences in drafting and negotiating ICFs in the UK versus the US. Stanfield and Wu were joined by Marc Dautlich and Alex Denoon, from Bristows LLP. To view a recording of this webinar, please refer to the video below.